RecruitingNCT07361289

A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy in China

A Single-Arm Observational Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy in China

Sponsor

Bristol-Myers Squibb

Enrollment

500 participants

Start Date

Jan 15, 2026

Study Type

OBSERVATIONAL

Conditions

Hypertrophic Cardiomyopathy

Summary

The purpose of this study is to assess the effectiveness of mavacamten treatment in Chinese adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM) in real-world clinical practice

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Mavacamten for people with hypertrophic cardiomyopathy. The study is currently recruiting participants at 15 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMavacamten

According to the product label

Locations(15)

Local Institution - 0008

Beijing, Beijing Municipality, China

Peking Union Medical College Hospital

Beijing, Beijing Municipality, China

Peking University First Affiliated Hospital

Beijing, Beijing Municipality, China

Local Institution - 0009

Guangzhou, Guangdong, China

The Second Afilliated Hospital of Hebei Medical University

Jiazhuang, Hebei, China

Local Institution - 0003

Harbin, Heilongjiang, China

Local Institution - 0007

Zhengzhou, Henan, China

Suzhou Municipal Hospital

Suzhou, Jiangsu, China

The Second Hospital of Jilin University

Changchun, Jilin, China

Local Institution - 0005

Dalian, Liaoning, China

Local Institution - 0013

Xi'an, Shan3xi, China

West China Hospital of Sichuan University

Chengdu, Sichuan, China

The Second Affiliated Hospital of Zhejiang University School of Medicine

Hangzhou, Zhejiang, China

Local Institution - 0010

Jinan, China

Zhongshan Hospital Fudan University

Shanghai, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07361289

Related Trials

Pediatric Cardiomyopathy Mutation Analysis

NCT024320921 location

Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM

NCT0583625910 locations

A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy in China

Conditions

Summary

Eligibility

Plain Language Summary

Interventions

Locations(15)

Related Trials

Pediatric Cardiomyopathy Mutation Analysis

Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM

Institutional Registry of Rare Diseases

Austrian Hypertrophic Cardiomyopathy Registry

Exercise Intolerance in Non-obstructive Hypertrophic Cardiomyopathy